- Current evidence and clinical implications of aspirin resistance
- Clopidogrel and Pharmacogenomic Testing VHA Pharmacy Benefits.
- In what circumstances mht it be advantageous to use ticagrelor.
- Plavix EPAR - Product Information - European Medicines Agency
Current evidence and clinical implications of aspirin resistance
The DDI risk does not exhibit a class effect, eg, the effects of clopidogrel on cerivastatin versus other statins, the effects of proton pump inhibitors on clopidogrel (omeprazole, esomeprazole versus pantoprazole, rabeprazole), the effects of rifampicin on clopidogrel versus ticagrelor and prasugrel, and the effects of calcium channel blockers on clopidogrel (amlodipine versus P-glycoprotein-inhibiting calcium channel blockers).
Clopidogrel and Pharmacogenomic Testing VHA Pharmacy Benefits.
Prevention of atherothrombotic events Clopidogrel is indicated in: • Adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
In what circumstances mht it be advantageous to use ticagrelor.
Plavix at recommended doses forms less of the active metabolite and so has a reduced effect on platelet activity in patients who are homozygous for nonfunctional alleles of the CYP2C19 gene, (termed "CYP2C19 poor metabolizers").
Plavix EPAR - Product Information - European Medicines Agency
It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent. Clopidogrel is used to prevent heart attack and stroke in people who are at hh risk of these events, including those with a history of myocardial infarction and other forms of acute coronary syndrome, stroke, and those with peripheral artery disease.
Plavix and clinical implications:
Rating: 94 / 100
Overall: 98 Rates